RGNX has been in the news 750% more than usual
Feb 24, 2026, 3:33 PM
4.06%
What does RGNX do
REGENXBIO, a clinical-stage biotechnology company based in Rockville, Maryland, specializes in gene therapy using its NAV Technology Platform for retinal, neuromuscular, and neurodegenerative diseases. Its key therapies include ABBV-RGX-314, RGX-202, and RGX-121.
RGNX has been in the news recently: REGENXBIO Inc. is facing a class action lawsuit for alleged securities fraud related to investor activities between February 9, 2022, and January 27, 2026, with a registration deadline of April 14, 2026. The lawsuit follows a reported 17.8% decline in the company's stock price, which fell to $11.01.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.